Avac Event
On Friday, November 15, from 1-2pm ET, leading pharmacologists including Angela Kashuba (UNC), Craig Hendrix (Johns Hopkins) and Pete Anderson (University of Colorado) will join in a discussion on the important pharmacokinetic and pharmacodynamic questions related to F/TAF and TDF/FTC. We’ll explore questions about what drug levels matter, and where in the body drug needs to be to protect against HIV.
Register here.
Avac Event
On Thursday, October 26, colleagues from the Treatment Action Group (TAG), along with advocates, researchers and GPP practitioners, discussed the recommendations from TAG’s recently released white paper, HIV Research in the Era of PrEP: The Implications of TDF/FTC for Biomedical Prevention Trials.
The effectiveness and increasing availability of oral PrEP raises questions about how it should be incorporated into clinical trial designs for next-generation HIV prevention options. This paper explores ethics, the scientific literature to date, and advocates’ views on the issue.
Avac Event
The program is of interest to clinical investigators from across the globe to review current research and to discuss its implications for HIV management strategies. In addition to looking at these treatment issues, the Congress is moving into areas, such as prevention, with time in the program focused on pre-exposure prophylaxis (PrEP) and issues across Europe and beyond.
The important role of people living with HIV in treatment decisions and self-management continues to feature, and we look forward to a number of perspective from the community.
For more information, visit hivglasgow.org, or download a flyer.
Avac Event
At CROI 2018 we heard stories, saw new data, and had lots of questions about early PrEP rollout. On Wednesday, April 18th, AVAC and partners from Jilinde in Kenya and PZAT in Zimbabwe explored valuable resources for people working to deliver oral PrEP. See below for some of the tools and resources we will explored and discussed during the webinar.
All of these materials (and many more) can be found on PrEPWatch.org, the clearinghouse for oral PrEP efforts across the globe.
Avac Event
Hundreds of people tuned in to hear researchers discuss the available data on “time to protection” required for effective oral PrEP with TDF/FTC—i.e., how many doses must be taken to build up protective levels of the drug in the blood? The answer is—it varies. Not surprisingly then, so do the guidelines for PrEP use.
As webinar participants learned, the data are varied and subject to interpretation. The World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC) recommend different time frames to reach protection in their respective guidelines for oral PrEP use. Both of these recommendations are based on measurements of the amount of drug that accumulates in blood and/or tissue over a specific period of time. The studies of how drugs are taken into the body and how they leave the body is called “pharmacokinetics” and “pharmacodynamics” or “PK” and “PD” for short, as explained in our primer for advocates. There isn’t a single PK measurement that is associated with PrEP protection—so both WHO and CDC guidelines are based on inference.
AVAC hosted a follow-on webinar presentation where representatives from both the CDC and WHO reviewed their respective guidance development processes and the role, use, contexts and audience for guidance documents.
Watch the recording on YouTube, listen to an mp3 version or download the slides. Q&A starts approximately 55 minutes in.
Avac Event
The US CDC estimates that nearly 500,000 women in the US could benefit from using PrEP. But women’s uptake of PrEP is small compared to men’s because most women who might want it have never even heard of it. One of the most effective ways to raise most women’s awareness of PrEP is to get their health care providers (usually family planning clinics) talking to them about PrEP.
In this webinar we explored the education that needs to be done among those health care providers to make this happen and what is being done to be prioritize it, especially by federal agencies, state and local health departments.
Avac Event
Surveys and focus groups conducted with women demonstrate few women know about PrEP as an effective HIV prevention method and women are interested in learning more about PrEP as a potential option for themselves.
Join HIVE for a 1-hour discussion via Google Hangouts.
Avac Event
Participants learned about:
For more information, contact [email protected]. The flyer is available for download below.
Avac Event
The PrEP Access & Engagement Training was hosted by BTAN Bay Area and the Black AIDS Institute. Health care access, PrEP guidelines, how to engage in a conversation about PrEP, community mobilizing around PrEP and prevention and much more were discussed.
Avac Event
Heard about a “tail” for long-acting injectables and want to know more? Interested in the timeline for when people with HIV might have injectable drug options for treatment? Wondering how people felt about getting an injection for PrEP? David Margolis (ViiV Healthcare) and Marty Markowitz (Aaron Diamond AIDS Research Center) spoke about long-acting injectable antiretrovirals for treatment and prevention.
Click for the slides and an audio recording. A link to the Flash animation is below.
At CROI, Margolis presented findings from the LATTE 2 trial, which tested a pair of long-acting injectables—cabotegravir (from ViiV Healthcare) and rilpivarine (from Janssen)—for HIV maintenance therapy, and Markowitz presented findings from the ÉCLAIR paste 2A study of cabotegravir in HIV-uninfected men.
And this webinar is part of our post-2016 CROI webinar series. Click for more information.